Unmet Needs With Car T Therapy in Multiple Myeloma: Nina Shah, MD

Video

The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Nina Shah, MD, hematologist/oncologist and associate professor of medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, about unmet needs with CAR T-cell therapy in multiple myeloma.

Shah discussed how CAR T-cell therapy has not quite managed to cure patients with multiple myeloma and no plateau has been seen on the survival curves, although the therapies have been a welcome addition to the treatment landscape. Innovative ways to prolong the efficacy of CAR T-cell therapy are being investigated, Shah said.

Unique culturing techniques, such as those utilized with the investigational bb21217 product, are being evaluated. Additionally, engineering techniques aimed at increasing the T-stem cell–like memory phenotype are being studied with the P-BCMA-101 product. Finally, allogenic CAR T-cell therapies, such as those being developed by Allogene Therapeutics, have the potential to increase accessibility to CAR T-cell therapy in multiple myeloma, Shah explained.

Ultimately, refining the culturing, engineering, and manufacturing process of CAR T-cell therapy may improve the success of this therapeutic modality and provide prolonged responses to patients with multiple myeloma, Shah concluded.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.